Renovaro BioSciences

Executive Summary

Renovaro BioSciences (operating as Lunai Bioworks) is a private, pre-clinical biotechnology company that leverages artificial intelligence, phenomics, and living biological systems to decode disease biology and accelerate drug discovery. Its integrated platform analyzes dynamic biological data at scale to identify clinically relevant therapeutic targets and biomarkers, bridging computational predictions with experimental validation in living models. Founded in 2013 and headquartered in Los Angeles, the company operates in the biologics, cell & gene therapy, and vaccines sectors. While still in early development, Renovaro's approach aims to de-risk drug discovery by combining AI-driven insights with wet-lab confirmation. The company has not yet disclosed specific pipeline programs, funding details, or partnerships, and remains in a pre-revenue stage. Its success will depend on advancing platform validation, securing financing, and forming strategic collaborations to move toward IND-enabling studies.

Upcoming Catalysts (preview)

• TBDSeries A or Seed Extension Financing Round60% success
• TBDLead Candidate Nomination for a Therapeutic Program40% success
• TBDPharmaceutical or Academic Collaboration Announcement30% success